GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » Return-on-Tangible-Asset

Biotest AG (Biotest AG) Return-on-Tangible-Asset : 8.33% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Biotest AG Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biotest AG's annualized Net Income for the quarter that ended in Mar. 2024 was $128.3 Mil. Biotest AG's average total tangible assets for the quarter that ended in Mar. 2024 was $1,539.3 Mil. Therefore, Biotest AG's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 8.33%.

The historical rank and industry rank for Biotest AG's Return-on-Tangible-Asset or its related term are showing as below:

BIESF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -8.68   Med: -1.61   Max: 18.28
Current: 15.68

During the past 13 years, Biotest AG's highest Return-on-Tangible-Asset was 18.28%. The lowest was -8.68%. And the median was -1.61%.

BIESF's Return-on-Tangible-Asset is ranked better than
95.94% of 1550 companies
in the Biotechnology industry
Industry Median: -40.42 vs BIESF: 15.68

Biotest AG Return-on-Tangible-Asset Historical Data

The historical data trend for Biotest AG's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG Return-on-Tangible-Asset Chart

Biotest AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.44 -2.97 -5.52 -2.70 9.97

Biotest AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.96 7.54 35.88 11.43 8.33

Competitive Comparison of Biotest AG's Return-on-Tangible-Asset

For the Biotechnology subindustry, Biotest AG's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biotest AG's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest AG's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biotest AG's Return-on-Tangible-Asset falls into.



Biotest AG Return-on-Tangible-Asset Calculation

Biotest AG's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=138.495/( (1256.991+1522.246)/ 2 )
=138.495/1389.6185
=9.97 %

Biotest AG's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=128.26/( (1522.246+1556.305)/ 2 )
=128.26/1539.2755
=8.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Biotest AG  (OTCPK:BIESF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biotest AG Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Biotest AG's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Biotest AG (Biotest AG) Business Description

Traded in Other Exchanges
Address
Landsteinerstrasse 5, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.

Biotest AG (Biotest AG) Headlines

From GuruFocus

Q4 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2022 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q3 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Full Year 2019 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Q4 2021 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024

Nine Months 2020 Biotest AG Earnings Call Transcript

By GuruFocus Research 03-03-2024